In sterile injectable manufacturing, succinylcholine chloride is processed as an aqueous solution at 20 mg/mL or 50 mg/mL expressed on an anhydrous basis, with sodium chloride added to reach an osmolality of 280–330 mOsm/kg. The formulation pH is maintained between 3.0 and 4.5 with hydrochloric acid or sodium hydroxide because the bis-quaternary ammonium di-ester undergoes base-catalysed hydrolysis to succinic acid and choline above pH 5.0. Terminal autoclaving cannot be used for this ester-containing molecule; the solution is instead passed through a 0.22 μm polyethersulfone membrane and filled into Type I borosilicate glass vials under nitrogen overlay. Stoppers are silicone-coated chlorobutyl rubber selected for low extractables per 21 CFR 211.94(a), and in-process controls include filter integrity testing, bioburden before filtration, pH, osmolality, and bacterial endotoxin limits following USP <1>. The API is pre-dried when relative humidity exceeds 60% because the powder is hygroscopic and water uptake accelerates ester cleavage before compounding. Multidose presentations may contain methylparaben 0.18% and propylparaben 0.02%, but single-use vials for intravenous administration in food-producing species generally avoid preservatives to reduce injection-site reactions and regulatory residue concerns. The finished injection is used only with independent mechanical ventilation because succinylcholine paralyses the diaphragm and other respiratory muscles; therefore the solution is not a sole anaesthetic and must be administered in a clinical setting with capnography and pulse oximetry. Batch-to-batch variance in pH and water content of the raw API from different suppliers requires pre-formulation titration of alkali because the dihydrate form can release free acid during storage.

Why Does Lyophilised Succinylcholine Require a Residual Moisture Specification Below 1.0% w/w?

Freeze-dried succinylcholine chloride is produced for markets where cold-chain distribution is unreliable or where multiday field use demands reduced hydrolytic activity. The liquid formulation containing succinylcholine chloride and a bulking agent such as mannitol or glycine is sterile-filtered, filled into vials, and lyophilized. The exact collapse temperature of this API matrix has not been published in a compendial monograph; thermal characterization by differential scanning calorimetry is therefore required during cycle scale-up, and published data for this specific configuration is limited. Residual moisture is controlled to below 1.0% w/w by Karl Fischer titration per USP <921> because water remaining in the amorphous cake accelerates hydrolytic degradation during storage. Primary drying is conducted below the measured collapse temperature, and secondary drying raises the shelf temperature in controlled increments of not more than 5 °C per hour to avoid cake shrinkage. After lyophilization, the vials are sealed under vacuum or dry nitrogen with a moisture-impermeable stopper. Reconstitution with 0.9% sodium chloride injection or sterile water for injection yields a solution with pH 3.5–4.0; the reconstituted product is used within 24 hours at 2–8 °C. A critical process conflict occurs with residual water and stopper moisture: chlorobutyl stoppers can retain adsorbed water after steam sterilization, and stopper drying below 0.1% residual moisture is often specified to avoid transferring water into the cake after sealing. The lyophilized dosage form permits reconstitution to a lower or higher concentration for species-specific dosing, but high-concentration reconstitution above 50 mg/mL is not recommended without viscosity and osmolality checks because succinylcholine chloride contributes ionic strength that can exceed isotonicity and cause local pain or haemolysis on intravenous injection. Stability protocols for the powder follow ICH Q1A(R2) with long-term storage at 2–8 °C and accelerated conditions at 25 °C/60% RH; hydrolytic degradation is monitored by a stability-indicating liquid chromatography method capable of separating succinic acid, choline, and the intact dicholine ester.

Concentrated Premix Dilution in Large-Animal Operating Room Fluid Lines

A 50 mg/mL concentrated aqueous solution is supplied to veterinary teaching hospitals and equine surgical centres for dilution into infusion bags. The concentrated solution is transferred into 0.9% sodium chloride or 5% dextrose injection using a vented dispensing pin in an ISO 14644-1 Class 5 environment or a properly maintained pharmacy isolator to preserve sterility. Final working concentrations of 1–2 mg/mL are common for adult large-animal protocols, but the exact dilution is determined by the patient’s body mass, plasma cholinesterase activity, and intended duration of neuromuscular blockade. Admixture is prepared immediately before use because diluted succinylcholine undergoes pH-dependent hydrolysis when held in polyvinyl chloride infusion bags for extended periods. The admixture should not be compounded in lactated Ringer’s solution with pH above 6.5; the rise in pH shortens the chemical stability window, and published physical compatibility data for this specific configuration is limited. Line flushing with normal saline before and after administration prevents contact with alkaline residues from previous drugs. Thiopental sodium and other alkaline barbiturate solutions are physically incompatible with succinylcholine because the acidic succinylcholine salt can protonate the barbiturate anion and form insoluble free acid precipitates; separate intravenous access or complete flushing with at least 10 mL of saline is required. The diluted solution is not heat-sterilizable and is not retained beyond 24 hours when refrigerated at 2–8 °C. Batch records for hospital admixture must capture the API lot number because succinylcholine chloride assay potency can decrease if the concentrated solution has been subjected to freeze-thaw cycling during transport; freeze-thaw cycles are avoided because phase separation and ice crystal formation can alter the pH and produce local high-solubility zones.

For remote chemical restraint of free-ranging ungulates, a concentrated aqueous formulation is loaded into 1-mL to 3-mL aluminium or polymer dart syringes in the field. The limiting factor is not API potency alone but the concentration-volume relationship: a dart with a final volume above 3 mL produces excessive impact trauma in small-bodied species, while a concentration above 50 mg/mL increases injection viscosity and can delay intramuscular absorption from the dart site. Dosing must be species-specific because succinylcholine has a narrow therapeutic index and its effect is terminated primarily by plasma pseudocholinesterase; animals with low cholinesterase activity from organophosphate exposure, hepatic compromise, or genetic variation exhibit prolonged paralysis and apnoea. The capture team must have a mechanical ventilation device or immediate endotracheal intubation capability, and the animal must be positioned to protect airway patency. The preparation is not suitable as a sole agent for prolonged transport; additional approved sedative-analgesic agents are used in sequence under veterinary supervision. Published data for this specific configuration is limited across non-domestic species, so regulatory submission for zoo and wildlife use typically requires target-animal safety studies under a national competent authority, with case data from captive animals rather than extrapolation from domestic cattle or horses. Environmental temperature affects drug performance: at ambient temperatures below 5 °C, the aqueous solution can cool rapidly in the dart and increase tissue irritation; at temperatures above 35 °C, the API in a transparent dart barrel can degrade if the dart is exposed to direct sunlight for more than several hours. The dart barrel is wrapped or shielded to reduce ultraviolet exposure because light exposure can accelerate aqueous hydrolysis of quaternary ammonium ester solutions, although published kinetic data under field conditions is limited.

When Multi-Dose Vial Preservatives Are Evaluated Against Pharmacopoeial Antimicrobial Effectiveness Criteria

Multidose vial presentations containing 0.18% methylparaben and 0.02% propylparaben must pass antimicrobial effectiveness testing according to Ph. Eur. 5.1.3 or USP <51>. The preservative system is tested during formulation development because succinylcholine chloride itself is not antimicrobial and the low pH of 3.0–4.5 does not by itself prevent microbial growth across all challenge organisms. The test procedure inoculates the multidose formulation with standard bacterial and fungal strains, including Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus brasiliensis, and requires specified log reductions at 6 hours, 24 hours, 7 days, and 28 days. The presence of methylparaben can interact with the silicone coating of chlorobutyl stoppers by sorption, reducing free preservative concentration below effective levels; stopper sorption studies are therefore performed using high-performance liquid chromatography at 2–8 °C and 25 °C over the proposed shelf life. Preservative-free single-dose vials avoid this interaction but are limited to one entry per patient because no antimicrobial protection exists after needle puncture. In veterinary anaesthesia where a large-animal facility may draw from the same vial for multiple patients in a single day, the multidose format reduces waste but introduces a contamination risk that must be controlled by strict aseptic technique and a maximum in-use period of 28 days unless otherwise justified by in-use stability data. The preservative combination is not used in intrathecal, epidural, or intra-articular routes because of neurotoxicity and cartilage damage potential; succinylcholine is administered intravenously or intramuscularly only.

During equine field anaesthesia, the injectable solution is administered by slow intravenous bolus after pre-anaesthetic sedation, and the horse is immediately intubated or fitted with a bag-valve-mask device. The onset of neuromuscular blockade occurs within 30–60 seconds of intravenous injection, with apnoea preceding loss of consciousness if sedation is inadequate; this sequence makes the product unsuitable for personnel without airway-management training. Heart rate and arterial blood pressure may rise because succinylcholine can stimulate autonomic ganglia and precipitate transient cardiac arrhythmias; continuous electrocardiography is used. The duration of induced paralysis is short, typically 5–10 minutes after an intravenous dose in domestic species, but is extended in animals with low plasma cholinesterase or after repeated doses. Repeated bolus administration may lead to dual block or phase II block, which cannot be reversed with neostigmine in all species and may require prolonged mechanical ventilation. This operational boundary is recorded on the anaesthetic chart, and a second veterinary team member is assigned to monitor jaw tone and corneal reflex return before anaesthetic recovery. The vial is not warmed in a microwave or water bath above 25 °C because ester hydrolysis accelerates at higher temperatures, and the unopened vial is kept in an insulated cooler when ambient temperature exceeds 30 °C. The solution is not mixed with alkaline emergency drugs such as sodium bicarbonate or thiopental sodium in the same line; incompatible admixture can form visible precipitates that obstruct intravenous catheters. Because succinylcholine is a quaternary ammonium compound, it does not cross lipid membranes rapidly; the volume of distribution is small and the plasma concentration-time profile is best described by a two-compartment model with rapid elimination, but published kinetic parameters for specific veterinary species are not uniformly available.

Oral Granule and Tablet Route Exclusion Data

The bis-quaternary ammonium structure of succinylcholine chloride results in negligible passive intestinal permeability, and any swallowed dose is exposed to intestinal esterases and plasma cholinesterase before reaching the neuromuscular junction. No published oral bioavailability data in target animal species supports a therapeutic window for tablets, capsules, powders, granules, or feed premixes; therefore these oral dosage forms are not recommended and are not represented in approved veterinary formularies. A feed premix route is additionally inappropriate because the narrow therapeutic index would make uniform mixing in feed an uncontrolled variable, with batch-to-batch segregation in high-fat meal formulations. The powder form can be used only as an intermediate for sterile dissolution and filtration; it is not distributed as a dry oral premix.